Fig. 5 | Scientific Reports

Fig. 5

From: Vildagliptin modulates the microbiota and induces an immunometabolic profile compatible with neuroprotection in type 2 diabetes

Fig. 5

Vildagliptin improved insulin resistance and promoted an intestinal microbial profile linked to beneficial functions, including SCFA production and an anti-inflammatory cytokine profile. Additionally, the slight modulation of the microbiota was accompanied by increased metabolite levels associated with neuroprotection. Together, these findings provide a potential explanation for the neuroprotective effects observed with DPP-4 inhibitors.

Back to article page